Literature DB >> 15057876

Increasing the sample size when the unblinded interim result is promising.

Y H Joshua Chen1, David L DeMets, K K Gordon Lan.   

Abstract

Increasing the sample size based on unblinded interim result may inflate the type I error rate and appropriate statistical adjustments may be needed to control the type I error rate at the nominal level. We briefly review the existing approaches which allow early stopping due to futility, or change the test statistic by using different weights, or adjust the critical value for final test, or enforce rules for sample size recalculation. The implication of early stopping due to futility and a simple modification to the weighted Z-statistic approach are discussed. In this paper, we show that increasing the sample size when the unblinded interim result is promising will not inflate the type I error rate and therefore no statistical adjustment is necessary. The unblinded interim result is considered promising if the conditional power is greater than 50 per cent or equivalently, the sample size increment needed to achieve a desired power does not exceed an upper bound. The actual sample size increment may be determined by important factors such as budget, size of the eligible patient population and competition in the market. The 50 per cent-conditional-power approach is extended to a group sequential trial with one interim analysis where a decision may be made at the interim analysis to stop the trial early due to a convincing treatment benefit, or to increase the sample size if the interim result is not as good as expected. The type I error rate will not be inflated if the sample size may be increased only when the conditional power is greater than 50 per cent. If there are two or more interim analyses in a group sequential trial, our simulation study shows that the type I error rate is also well controlled. Copyright 2004 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15057876     DOI: 10.1002/sim.1688

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  20 in total

1.  Luteal versus follicular phase surgical oophorectomy plus tamoxifen in premenopausal women with metastatic hormone receptor-positive breast cancer.

Authors:  Richard R Love; Syed Mozammel Hossain; Md Margub Hussain; Mohammad Golam Mostafa; Adriano V Laudico; Stephen Sixto S Siguan; Clement Adebamowo; Jing-Zhong Sun; Fei Fei; Zhi-Ming Shao; Yunjiang Liu; Syed Md Akram Hussain; Baoning Zhang; Lin Cheng; Sonar Panigaro; Fardiana Walta; Jiang Hong Chuan; Maria Rica Mirasol-Lumague; Cheng-Har Yip; Narciso S Navarro; Chiun-Sheng Huang; Yen-Shen Lu; Tahmina Ferdousy; Reza Salim; Chameli Akhter; Shamsun Nahar; Gemma Uy; Gregory S Young; Erinn M Hade; David Jarjoura
Journal:  Eur J Cancer       Date:  2016-04-20       Impact factor: 9.162

2.  A new method to orient 3-dimensional computed tomography models to the natural head position: a clinical feasibility study.

Authors:  James J Xia; J Kevin McGrory; Jaime Gateno; John F Teichgraeber; Brian C Dawson; Kathleen A Kennedy; Robert E Lasky; Jeryl D English; Chung H Kau; Kathleen R McGrory
Journal:  J Oral Maxillofac Surg       Date:  2011-03       Impact factor: 1.895

3.  Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls.

Authors:  Peter Bauer; Frank Bretz; Vladimir Dragalin; Franz König; Gernot Wassmer
Journal:  Stat Med       Date:  2015-03-16       Impact factor: 2.373

Review 4.  OARSI Clinical Trials Recommendations: Key analytic considerations in design, analysis, and reporting of randomized controlled trials in osteoarthritis.

Authors:  E Losina; J Ranstam; J E Collins; T J Schnitzer; J N Katz
Journal:  Osteoarthritis Cartilage       Date:  2015-05       Impact factor: 6.576

5.  Options and Considerations for Adaptive Laboratory Experiments.

Authors:  Lai Wei; David Jarjoura
Journal:  Stat Biosci       Date:  2014-11-25

6.  Adaptive Budgets in Clinical Trials.

Authors:  Martin Posch; Peter Bauer
Journal:  Stat Biopharm Res       Date:  2013-04-04       Impact factor: 1.452

7.  The prospective randomized trial of the optimal evaluation of cardiac symptoms and revascularization: Rationale and design of the PRECISE trial.

Authors:  Michael G Nanna; Sreekanth Vemulapalli; Christopher B Fordyce; Daniel B Mark; Manesh R Patel; Hussein R Al-Khalidi; Michelle Kelsey; Beth Martinez; Eric Yow; Sarah Mullen; Gregg W Stone; Ori Ben-Yehuda; James E Udelson; Campbell Rogers; Pamela S Douglas
Journal:  Am Heart J       Date:  2021-12-23       Impact factor: 4.749

8.  Will Mobile Diabetes Education Teams (MDETs) in primary care improve patient care processes and health outcomes? Study protocol for a randomized controlled trial.

Authors:  Enza Gucciardi; Mariella Fortugno; Stacey Horodezny; Wendy Lou; Souraya Sidani; Sherry Espin; Fiona Webster; Baiju R Shah
Journal:  Trials       Date:  2012-09-13       Impact factor: 2.279

Review 9.  Clinical Research Needs for the Management of Chronic Rhinosinusitis with Nasal Polyps in the New Era of Biologics: A National Institute of Allergy and Infectious Diseases Workshop.

Authors:  Robert Naclerio; Fuad Baroody; Claus Bachert; Benjamin Bleier; Larry Borish; Erica Brittain; Geoffrey Chupp; Anat Fisher; Wytske Fokkens; Philippe Gevaert; David Kennedy; Jean Kim; Tanya M Laidlaw; Jake J Lee; Jay F Piccirillo; Jayant M Pinto; Lauren T Roland; Robert P Schleimer; Rodney J Schlosser; Julie M Schwaninger; Timothy L Smith; Bruce K Tan; Ming Tan; Elina Toskala; Sally Wenzel; Alkis Togias
Journal:  J Allergy Clin Immunol Pract       Date:  2020-03-04

10.  Statistical conclusion validity: some common threats and simple remedies.

Authors:  Miguel A García-Pérez
Journal:  Front Psychol       Date:  2012-08-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.